ZA200302525B - Ribavirin-pegylated interferon alfa HCV combination therapy. - Google Patents

Ribavirin-pegylated interferon alfa HCV combination therapy. Download PDF

Info

Publication number: ZA200302525B
Authority: ZA; South Africa
Prior art keywords: interferon alfa; ribavirin; pegylated interferon; treatment; composition
Prior art date: 2000-10-18

Application number

ZA200302525A

Other languages

English (en)

Inventor

Janice Albrecht

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-18

Filing date

2003-03-31

Publication date

2004-07-21

2003-03-31 Application filed by Schering Corp filed Critical Schering Corp

2004-07-21 Publication of ZA200302525B publication Critical patent/ZA200302525B/en

Links

108010047761 Interferon-alpha Proteins 0.000 title claims description 49
102000006992 Interferon-alpha Human genes 0.000 title claims description 49
229950000038 interferon alfa Drugs 0.000 title claims description 43
238000002648 combination therapy Methods 0.000 title description 5
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 117
229960000329 ribavirin Drugs 0.000 claims description 88
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 88
238000011282 treatment Methods 0.000 claims description 64
108010092851 peginterferon alfa-2b Proteins 0.000 claims description 45
238000000034 method Methods 0.000 claims description 31
239000000203 mixture Substances 0.000 claims description 29
208000020403 chronic hepatitis C virus infection Diseases 0.000 claims description 23
102000014150 Interferons Human genes 0.000 claims description 17
108010050904 Interferons Proteins 0.000 claims description 17
210000002966 serum Anatomy 0.000 claims description 17
108010078049 Interferon alpha-2 Proteins 0.000 claims description 16
230000037396 body weight Effects 0.000 claims description 14
229940079322 interferon Drugs 0.000 claims description 14
229960003507 interferon alfa-2b Drugs 0.000 claims description 11
241000711549 Hepacivirus C Species 0.000 claims description 9
230000003612 virological effect Effects 0.000 claims description 9
MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 claims description 8
108010092853 peginterferon alfa-2a Proteins 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
229960003521 interferon alfa-2a Drugs 0.000 claims description 6
230000003442 weekly effect Effects 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 5
108010054698 Interferon Alfa-n3 Proteins 0.000 claims description 3
108010055511 interferon alfa-2c Proteins 0.000 claims description 3
108010006088 interferon alfa-n1 Proteins 0.000 claims description 3
229940109242 interferon alfa-n3 Drugs 0.000 claims description 3
239000000126 substance Substances 0.000 claims 23
229960004061 interferon alfa-n1 Drugs 0.000 claims 2
229940106366 pegintron Drugs 0.000 description 22
230000004044 response Effects 0.000 description 17
229940053146 rebetol Drugs 0.000 description 16
108010012770 Rebetron Proteins 0.000 description 12
108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
230000002459 sustained effect Effects 0.000 description 9
230000000694 effects Effects 0.000 description 8
208000005176 Hepatitis C Diseases 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
238000010839 reverse transcription Methods 0.000 description 7
241000700605 Viruses Species 0.000 description 6
208000010710 hepatitis C virus infection Diseases 0.000 description 6
229940065638 intron a Drugs 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
208000006154 Chronic hepatitis C Diseases 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 4
102100040019 Interferon alpha-1/13 Human genes 0.000 description 4
238000002105 Southern blotting Methods 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000000523 sample Substances 0.000 description 4
238000011269 treatment regimen Methods 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
108010079944 Interferon-alpha2b Proteins 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229940047124 interferons Drugs 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000009265 virologic response Effects 0.000 description 3
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
102100040018 Interferon alpha-2 Human genes 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000001514 detection method Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000012744 immunostaining Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
239000008176 lyophilized powder Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
229920000233 poly(alkylene oxides) Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
VVLAIYIMMFWRFW-UHFFFAOYSA-N 2-hydroxyethylazanium;acetate Chemical compound CC(O)=O.NCCO VVLAIYIMMFWRFW-UHFFFAOYSA-N 0.000 description 1
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241001227713 Chiron Species 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108020005719 Species specific proteins Proteins 0.000 description 1
102000007397 Species specific proteins Human genes 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
YDQXYRCYDMRJGD-UHFFFAOYSA-N chloroform;phenol;thiocyanic acid Chemical compound SC#N.ClC(Cl)Cl.OC1=CC=CC=C1 YDQXYRCYDMRJGD-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000008029 eradication Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000003205 genotyping method Methods 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
238000010606 normalization Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229940002988 pegasys Drugs 0.000 description 1
229960003930 peginterferon alfa-2a Drugs 0.000 description 1
229960003931 peginterferon alfa-2b Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
-1 polyethylene Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
238000012340 reverse transcriptase PCR Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses

ZA200302525A 2000-10-18 2003-03-31 Ribavirin-pegylated interferon alfa HCV combination therapy. ZA200302525B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US24155700P	2000-10-18	2000-10-18

Publications (1)

Publication Number	Publication Date
ZA200302525B true ZA200302525B (en)	2004-07-21

Family

ID=22911172

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200302525A ZA200302525B (en)	2000-10-18	2003-03-31	Ribavirin-pegylated interferon alfa HCV combination therapy.

Country Status (13)

Country	Link
US (1)	US20020127203A1 (fr)
EP (1)	EP1326594A2 (fr)
JP (1)	JP2004511513A (fr)
CN (1)	CN1516599A (fr)
AU (1)	AU2002213343A1 (fr)
BR (1)	BR0114636A (fr)
CA (1)	CA2425522A1 (fr)
HK (1)	HK1052878A1 (fr)
HU (1)	HUP0301444A3 (fr)
MX (1)	MXPA03003456A (fr)
NO (1)	NO20031742L (fr)
WO (1)	WO2002032414A2 (fr)
ZA (1)	ZA200302525B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
EP1294735A2 (fr)	2000-05-26	2003-03-26	Novirio Pharmaceuticals Limited	Procedes et compositions de traitement des flavivirus et des pestivirus
WO2003049760A1 (fr) *	2001-12-07	2003-06-19	Intermune, Inc.	Compositions et procede de traitement de l'infection par le virus de l'hepatite
ATE290387T1 (de) *	2001-12-21	2005-03-15	Biopartners Gmbh	Ribavirin-granulat zur herstellung von filmtabletten
RS114004A (en)	2002-06-28	2007-02-05	Idenix (Cayman) Limited,	Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
KR20050035194A (ko) *	2002-06-28	2005-04-15	이데닉스 (케이만) 리미티드	플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
US7608600B2 (en)	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN1849142A (zh)	2002-11-15	2006-10-18	埃迪尼克斯(开曼)有限公司	2′－支链核苷和黄病毒突变
AU2003300434A1 (en) *	2002-12-23	2004-07-22	Idenix (Cayman) Limited	Process for the production of 3'-nucleoside prodrugs
EP2345661A1 (fr)	2003-05-30	2011-07-20	Pharmasset, Inc.	Analogues de nucléosides fluores modifiés
NZ545159A (en) *	2003-08-13	2009-03-31	Smith Howard J & Ass Pty Ltd	Method of treating viral infections
US7595318B2 (en) *	2004-01-23	2009-09-29	Elan Pharmaceuticals, Inc.	Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
EP1912643A2 (fr) *	2004-06-23	2008-04-23	Idenix (Cayman) Limited	Derives de5-aza-7-deazapurine pour le traitement des infections a flaviviridae
JP4849622B2 (ja)	2004-08-11	2012-01-11	中外製薬株式会社	Ｈｃｖ感染症を治療または予防するための薬剤
AU2005285045B2 (en)	2004-09-14	2011-10-13	Gilead Pharmasset Llc	Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
EP1976382B1 (fr)	2005-12-23	2013-04-24	IDENIX Pharmaceuticals, Inc.	Procede pour la preparation d'un intermediaire synthetique pour la preparation de nucleosides ramifies
JPWO2007132882A1 (ja) *	2006-05-16	2009-09-24	財団法人東京都医学研究機構	Ｈｃｖ感染症を治療または予防するための医薬組成物
EP2050459B1 (fr) *	2006-07-07	2013-03-13	Meiji Seika Pharma Co., Ltd.	Agent prophylactique ou thérapeutique pour une maladie virale
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
US8793074B2 (en) *	2007-06-21	2014-07-29	Saint Louis University	Sequence covariance networks, methods and uses therefor
TW200946541A (en)	2008-03-27	2009-11-16	Idenix Pharmaceuticals Inc	Solid forms of an anti-HIV phosphoindole compound
WO2010061881A1 (fr)	2008-11-26	2010-06-03	中外製薬株式会社	Ologoribonucléotide ou acide nucléique de peptide capable d'inhiber l'activité du virus de l'hépatite c
SG172361A1 (en)	2008-12-23	2011-07-28	Pharmasset Inc	Nucleoside analogs
AR074897A1 (es)	2008-12-23	2011-02-23	Pharmasset Inc	Fosforamidatos de nucleosidos
AU2009329872B2 (en)	2008-12-23	2016-07-07	Gilead Pharmasset Llc	Synthesis of purine nucleosides
TWI583692B (zh)	2009-05-20	2017-05-21	基利法瑪席特有限責任公司	核苷磷醯胺
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
JPWO2011001897A1 (ja) *	2009-06-30	2012-12-13	ＭｅｉｊｉＳｅｉｋａファルマ株式会社	難治性のｃ型慢性肝炎の治療のための薬剤及び方法
WO2011002584A1 (fr) *	2009-07-02	2011-01-06	The University Of Iowa Research Foundation	Traitement des infections par le virus de l'hépatite c
EP2752422B1 (fr)	2010-03-31	2017-08-16	Gilead Pharmasset LLC	Synthèse stéréosélective d'agents actifs contenant du phosphore
WO2011153514A2 (fr)	2010-06-03	2011-12-08	Pharmacyclics, Inc.	Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
ES2716158T3 (es)	2010-11-30	2019-06-10	Gilead Pharmasset Llc	2'-spiro-nucleótidos para el tratamiento de hepatitis C
MD4589C1 (ro)	2011-09-16	2019-03-31	Gilead Pharmasset Llc	Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
US8853176B2 (en)	2011-10-21	2014-10-07	Abbvie Inc.	Methods for treating HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
GB2515942A (en)	2011-10-21	2015-01-07	Abbvie Inc	Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
JP6575950B2 (ja)	2012-07-24	2019-09-18	ファーマサイクリックスエルエルシー	Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
CN111329989A (zh)	2012-11-02	2020-06-26	药品循环有限责任公司	Tec家族激酶抑制剂辅助疗法
NZ625087A (en)	2013-01-31	2017-05-26	Gilead Pharmasset Llc	Combination formulation of two antiviral compounds
ES2900570T3 (es)	2013-08-27	2022-03-17	Gilead Pharmasset Llc	Formulación de combinación de dos compuestos antivirales
US9885086B2 (en)	2014-03-20	2018-02-06	Pharmacyclics Llc	Phospholipase C gamma 2 and resistance associated mutations
WO2017189978A1 (fr)	2016-04-28	2017-11-02	Emory University	Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6387365B1 (en) *	1995-05-19	2002-05-14	Schering Corporation	Combination therapy for chronic hepatitis C infection
JP2000507917A (ja) *	1995-11-02	2000-06-27	シェーリングコーポレイション	持続的低用量サイトカイン注入治療
US6172046B1 (en) *	1997-09-21	2001-01-09	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
WO1999059621A1 (fr) *	1998-05-15	1999-11-25	Schering Corporation	Therapeutique associee comprenant la ribavirine et l'interferon alpha utilisee pour traiter des novices aux essais cliniques atteints de l'hepatite c chronique
US6403564B1 (en) *	1998-10-16	2002-06-11	Schering Corporation	Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6277830B1 (en) *	1998-10-16	2001-08-21	Schering Corporation	5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6824768B2 (en) *	1998-12-18	2004-11-30	Schering Corporation	Ribavirin-pegylated interferon alfa induction HCV combination therapy
JP2003507322A (ja) *	1998-12-18	2003-02-25	シェリング・コーポレーション	リバビリン−ＰＥＧ化インターフェロン−α誘発ＨＣＶ併用治療
US6685931B1 (en) *	1998-12-22	2004-02-03	Schering Corporation	Treatment of hepatitis C virus infections with interleukin-10
US6635646B1 (en) *	1999-05-04	2003-10-21	Schering Corporation	Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
AU2001255495A1 (en) *	2000-04-20	2001-11-07	Schering Corporation	Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
US6673775B2 (en) *	2001-04-18	2004-01-06	Schering Corporation	Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
WO2003024461A1 (fr) *	2001-09-20	2003-03-27	Schering Corporation	Polytherapie de l'hepatite c

2001
- 2001-10-16 US US09/981,215 patent/US20020127203A1/en not_active Abandoned
- 2001-10-16 EP EP01981718A patent/EP1326594A2/fr not_active Withdrawn
- 2001-10-16 HU HU0301444A patent/HUP0301444A3/hu unknown
- 2001-10-16 JP JP2002535652A patent/JP2004511513A/ja active Pending
- 2001-10-16 AU AU2002213343A patent/AU2002213343A1/en not_active Abandoned
- 2001-10-16 CA CA002425522A patent/CA2425522A1/fr not_active Abandoned
- 2001-10-16 CN CNA018176038A patent/CN1516599A/zh active Pending
- 2001-10-16 BR BR0114636-0A patent/BR0114636A/pt not_active IP Right Cessation
- 2001-10-16 MX MXPA03003456A patent/MXPA03003456A/es unknown
- 2001-10-16 WO PCT/US2001/032434 patent/WO2002032414A2/fr not_active Application Discontinuation
2003
- 2003-03-31 ZA ZA200302525A patent/ZA200302525B/en unknown
- 2003-04-15 NO NO20031742A patent/NO20031742L/no unknown
- 2003-07-17 HK HK03105160.0A patent/HK1052878A1/zh unknown

Also Published As

Publication number	Publication date
NO20031742L (no)	2003-06-17
MXPA03003456A (es)	2003-07-14
HUP0301444A3 (en)	2007-05-29
JP2004511513A (ja)	2004-04-15
CN1516599A (zh)	2004-07-28
AU2002213343A1 (en)	2002-04-29
HUP0301444A2 (hu)	2003-11-28
US20020127203A1 (en)	2002-09-12
WO2002032414A3 (fr)	2003-04-03
HK1052878A1 (zh)	2003-10-03
WO2002032414A2 (fr)	2002-04-25
CA2425522A1 (fr)	2002-04-25
BR0114636A (pt)	2004-02-10
EP1326594A2 (fr)	2003-07-16
NO20031742D0 (no)	2003-04-15

Publication	Publication Date	Title
US20020127203A1 (en)	2002-09-12	Ribavirin-pegylated interferon alfa HCV combination therapy
EP0956861B1 (fr)	2002-04-24	Thérapie combinatoire conténant de la ribavirine et de l'interferon alpha chez les patients ayant une infection chronique d'hépatite C et n'ayant pas été traités par un agent antiviral
US6472373B1 (en)	2002-10-29	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
Perry et al.	2001	Peginterferon-α-2a (40kD) A review of its use in the management of chronic hepatitis C
WO2000037110A2 (fr)	2000-06-29	Traitement du vhc par induction d'interferon-alpha pegyle combine la ribavirine
EP0903148B1 (fr)	2001-10-10	Thérapie combinée pour l'éradication de hcv-arn détectable chez des patients ayant une infection d'hépatite C chronique
US6824768B2 (en)	2004-11-30	Ribavirin-pegylated interferon alfa induction HCV combination therapy
ZA200108571B (en)	2003-01-20	HCV combination therapy, containing ribavirin in association with antioxidants.
US6849254B1 (en)	2005-02-01	HCV combination therapy
EP1140142A2 (fr)	2001-10-10	Traitement des infections du virus de l'hepatite c avec interleukine-10
WO2000037097A1 (fr)	2000-06-29	Polytherapie contre le virus de l'hepatite c, au moyen de la ribavirine et de l'induction de l'interferon alpha
EP1043025B1 (fr)	2005-06-01	Traitement du carcinome de cellules rénales
MXPA01006161A (en)	2001-12-13	Ribavirin-pegylated interferon alfa induction hcv combination therapy